As a pharmacist, few questions confuse my clients more than this one: “Does Medicare cover Ozempic, Wegovy, or Mounjaro?” The answer is not a simple yes or no — it depends on why the drug is prescribed, which drug it is, and what’s changed recently. Here’s the breakdown for 2026, based on the rules as of October 2026.
The Big Rule: No Part D Coverage for Weight Loss Alone
Let’s start with the hard line:
- Standard Medicare Part D does not cover GLP-1 drugs prescribed for weight loss alone.
- This is a federal law exclusion — weight-loss drugs have been excluded from Part D since the program began.
- CMS declined to finalize broader anti-obesity drug coverage in April 2025, so that exclusion still stands.
If weight management is the only reason for the prescription, a Part D plan cannot cover it. That’s the law, not the plan’s choice.
Where Part D CAN Cover GLP-1s
Part D can cover GLP-1 medications when they’re prescribed for other FDA-approved indications, including:
- Type 2 diabetes — Ozempic, Mounjaro, Trulicity, and Rybelsus.
- Cardiovascular-risk reduction — Wegovy.
- Moderate-to-severe obstructive sleep apnea with obesity — Zepbound.
But coverage is indication-specific: the plan covers the drug for the approved use, and it must be documented. Coverage also varies by plan formulary, and often requires prior authorization or step therapy. Check your plan’s drug list for your specific drug and diagnosis.
NEW: The Medicare GLP-1 Bridge Demonstration
This is the biggest recent change, and it’s worth understanding. The Medicare GLP-1 Bridge demonstration launched July 1, 2026 and runs through December 31, 2027. Here’s what it does:
- Eligible Part D beneficiaries pay a flat $50 per month for covered GLP-1 medications.
- Covered drugs: Wegovy (injection or tablet), Zepbound KwikPen only (no vials or single-dose pens), or Foundayo tablets.
- Eligibility is based on BMI tiers:
- BMI 35 or higher alone;
- BMI 30 or higher with heart failure, hard-to-control blood pressure, or chronic kidney disease stage 3a or above;
- BMI 27 or higher with prediabetes or a prior heart attack, stroke, or peripheral artery disease.
- The process: your doctor sends a prior-authorization request to Medicare’s central processor — not to your individual plan.
For full details, visit Medicare.gov/glp1bridge or call 1-800-MEDICARE.
My Pharmacist’s Advice: Verify Current Rules
This area of coverage is changing fast — demonstrations launch, formularies update, and rules shift. Everything above reflects the rules as of October 2026, but plan details can change year to year. Before making any decisions:
- Confirm your plan’s current formulary and any prior-authorization requirements.
- Ask your doctor whether your prescription matches a covered FDA-approved indication.
- If you think you qualify for the Bridge demonstration, talk to your prescriber about the eligibility criteria and the central prior-authorization process.
Want Help Sorting Through Your Options?
GLP-1 coverage is one of the trickiest corners of Medicare drug benefits, and getting it wrong can cost thousands. As a pharmacist, I read formularies and coverage rules for a living. Call me at (803) 415-7794 for a no-cost consultation, and we’ll review your medications and coverage together — plain answers, no obligation.